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Over 800 million people worldwide are infected with hepatitis viruses, human immunodeficiency virus (HIV),
and malaria, resulting in more than 5 million deaths annually. Here we discuss the potential and challenges of
humanized mouse models for developing effective and affordable therapies and vaccines, which are desper-
ately needed to combat these diseases.Infectious diseases continue to heavily
burden our global society. Chronic viral
infections, including those caused by
hepatitis B virus (HBV), hepatitis C virus
(HCV), andhuman immunodeficiencyvirus
(HIV), currently afflictmore than500million
people worldwide, cumulatively resulting
in more than 3.5 million deaths per year.
Bacterial and parasitic diseases have
a similarly high impact; Mycobacterium
tuberculosis frequently establishes persis-
tent infections, with an estimated 2 billion
carriers around the globe and an annual
mortality of close to 1.7 million individuals.
Endemic and epidemic malaria results in
severe disease in an estimated half-a-
billion people each year, and causes over
1.5milliondeathsannually. Althoughprog-
ress has been made in the prevention and
treatment of these infections, more effec-
tive, tolerable, and affordable therapies
are urgently needed.Many of these important pathogens
display unique human tropism, and the
development of novel intervention strate-
gies has been hampered by the lack of
robust, cost-effective, and predictive
animal models that accurately reproduce
the hallmarks of human infections. While
rodents and nonhuman primates have
been employed in biomedical research
and drug/vaccine development, they
often do not yield reliable preclinical
results that translate into effective human
treatments. Two important factors
contribute to this failure: (1) on the micro-
bial side, surrogate pathogens often differ
significantly from highly restricted human
counterparts; and (2) on the host side,
the immune correlates of protection in
nonhuman mammalian species often
diverge from human responses.
For decades large primates, especially
chimpanzees, have been used to studyCell Host & Miimmunobiology and candidate therapies
against human pathogens such as HIV,
HBV, and HCV. Although the genomes of
humansandchimpanzees are>98% iden-
tical, small differences can significantly
influence disease pattern and outcome
(Muchmore, 2001). For example, chim-
panzees and humans do not share any
human leukocyte antigen (HLA) class I
alleles, thecommonhumanallele (HLA-A2)
is completely absent in chimpanzees,
and clear differences in the MHC class II
region are also observed. As a conse-
quence nonhuman primates often do not
completely reproduce the pathophysi-
ology of human disease. In addition, use
of these large primates is expensive and
banned in many countries due to ethical
concerns. As a result, experiments using
limited numbers of outbred animals are
plagued by interindividual variability and
consequently have limited reproducibility.crobe 6, July 23, 2009 ª2009 Elsevier Inc. 5
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siderable roadblocks to vaccine develop-
ment. Current regulations for human
vaccine testing—among others the strin-
gent requirement for good manufacturing
practice (GMP) grade material for phase I
studies—have led to an explosive increase
in clinical development costs. To bridge
the translational gap, novel strategies are
needed for rapid andcost-efficient screen-
ing, selection, andprioritizationof themost
promising candidates.None of the existing
animal models adequately addresses the
needs of vaccine developers, nor do they
provide the detailed understanding of the
human immune response that is required
for generationof vaccinestrategiesagainst
pathogens that have closely co-evolved
with humans. Investigation of human
biology in vivo is hampered by severe
ethical and practical limitations—including
use of placebos and experimental drugs
prone to resistance selection, the risk
of discrimination or stigmatization as a
consequence of having participated in
the research, limited sample procurement,
and heterogeneity of the study population.
These limitations and lack of suitable
animal surrogates create a seemingly in-
surmountablebarrier to conducting essen-
tial preclinical investigations.
‘‘Humanized’’ mice have recently
emerged as powerful tools in the investi-
gation of human disease (reviewed in Le-
grand et al., 2006; Manz, 2007; Shultz
et al., 2007). These are amenable small
animal models transplanted with human
cells or tissues (and/or equipped with
human transgenes) that may be ideally
suited for direct investigation of human
infectious agents. Successful engraftment
depends on avoiding rejection and
maximizing tissue function, ensured by
correct localization and appropriate tissue
support by host factors. Despite the chal-
lenges, humanizedmouse technology has
made rapid progress over the last few
years, and it is now possible to achieve
high levels of human chimerism in various
host organs/tissues, particularly the
immune system, liver, and muscle. Such
humanized mice provide a new opportu-
nity to perform preclinical studies of
intractable human pathogens.
With a focus on HBV and HCV, HIV,
tuberculosis, and malaria, we here dis-
cuss the current status and future pros-
pects of mice carrying the target tissues
of human pathogens, as well as bearing6 Cell Host & Microbe 6, July 23, 2009 ª200human immune components to react
against them (Figure 1).
Toward Robust and Predictive
Small Animal Models of Human
Disease: Human Hematopoietic
and Immune System Mice
Human immune system (HIS) mice princi-
pally recapitulate the development of
human lymphoid compartment. HIS mice
are generated by grafting immunodefi-
cient animals with suspensions of hema-
topoietic progenitor cells and/or human
peripheral blood cells, and potentially
with supplemental human tissues sup-
porting the generation of human immune
cells (Gimeno et al., 2004; Ito et al.,
2002; Melkus et al., 2006; Traggiai et al.,
2004). HIS mice are already showing
potential as the only available small
animal challenge model for HIV infection,
a valuable platform for testing the
efficacy of antiviral compounds (Figure 1).
Importantly, these mice can be infected
with HIV not only intravenously but also
by relevant intravaginal and intrarectal
routes, making this model particularly
attractive for preclinical validation of anti-
microbial agents that are active at
mucosal surfaces (Denton et al., 2008;
Grant et al., 2008). Recent disappointing
clinical trial outcomes with anti-HIV
microbicides could have possibly been
predicted and avoided if sufficient preclin-
ical data of this type had been available
(Grant et al., 2008).
Despite their promise, immune
responses to infection remain suboptimal
in HIS mice. For instance, tetanus toxoid
immunizations result in lower antibody
levels in HIS mice than those achieved in
human adults (Traggiai et al., 2004). Only
very few HIV-infected HIS mice develop
virus-specific antibodies, and thus far
HIV-specific T cell responses have not
been observed (Baenziger et al., 2006).
Epstein Barr virus (EBV) infection of HIS
mice results in activation of T and B cells,
but can progress to B cell lymphoma, indi-
cating that these mice cannot control the
infection (Traggiai et al., 2004). Taken
together these data suggest that immu-
nity in humanized mice is not yet compa-
rable to humans and further development
is required before these mice can be
employed in screening human vaccine
candidates.
Currently, the total amount of human
cells in HIS mice is below the desired9 Elsevier Inc.level. Likewise, IgM and IgG serum titers
are substantially lower in HIS mice as
compared to humans. Hematopoietic
stem cells are insufficiently maintained,
and differentiation into particular lineages,
such as erythromyeloid cells, is ineffective
(Manz, 2007). The inadequate formation
of higher order lymphoid structures may
be central to this limited immune
response. Generation of a robust predic-
tive model for human immune responses
will therefore require significant improve-
ment of HIS mouse reconstitution and
function. Strategies to improve reconsti-
tution include enhancing the ablation of
endogenous mouse subsets to create
‘‘space’’ for human cells, providing exog-
enous cytokines to overcome impaired
biological crossreactivity between mouse
and human, counteracting active graft
destruction, and expressing human MHC
molecules to ensure proper T cell educa-
tion and homeostasis (Legrand et al.,
2006; Manz, 2007). Although each of
these modifications may only incremen-
tally improve the functionality of HIS
mice, the additive (and potentially syner-
gistic) effects of these different improve-
ments create optimism that a predictive
model for the human immune response
in mice can be achieved in the near future.
Use of these advanced animal models for
vaccine testing is expected to enhance
our ability to predict performance in
humans, and will thereby enable rapid
and efficient selection of the best vaccine
candidates for translation into the clinical
development pipeline.
Creating Human Liver Chimeric
Mice for the Study and Intervention
of Human Hepatotropic Pathogens
The human liver serves as the reservoir for
several important pathogens, including
hepatitis B and C viruses and the malaria
parasite Plasmodium falciparum, which
together are responsible for more than
half-a-billion infections and between 2.5
and 4.5 million deaths annually. Further-
more, the liver plays a critical role in
drug metabolism and detoxification, with
human hepatocytes showing unique
enzymatic profiles that are not recapitu-
lated in othermammalian species. Interest
in these critical avenues of human health
has spurred efforts to create animals
with human livers. A high degree of human
liver chimerism can be achieved by
transplanting human hepatocytes into
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The generation of pathogen-specific humanized mouse models is a long-term goal in order to better understand human pathogenesis and to test therapeutic
interventions in a preclinical setting. iPS, induced pluripotent stem cells; ES, embryonic stem cells; HSC, hematopoietic stem cells; LADME, liberation, absorp-
tion, distribution, metabolism, excretion.immunodeficient mice with liver injuries to
ablate endogenous murine hepatocytes.
The most advanced model—and best
characterized so far—is the urokinase-
type plasminogen activator (uPA) mouse,
inwhich a transgene driven by the albumin
enhancer/promoter directs high-level
hepatocyte-specific expression of the
toxin uPA (Mercer et al., 2001; Meuleman
et al., 2005). This creates an environment
for the transplanted, transgene-free,
human hepatocytes (HuHEP) to populate
the repairing mouse liver and to promote
survival of the animal. Indeed, HuHEP
mice are susceptible to hepatotropic
human pathogens and are therefore
invaluable tools for basic research and
preclinical applications (Mercer et al.,
2001; Meuleman et al., 2005) (Figure 1).
Due to the immunodeficient background
of the recipient, however, neither path-
ogen- nor vaccine-induced immune res-
ponses can be studied. Combination ofHuHEP mice with the above described
HIS mouse model will be critical to
surmount this shortcoming (Figure 1).
Beyond their use in studying host-path-
ogen interactions, human liver chimeric
mice have been employed for preclinical
evaluation of efficacy, toxicology, and
pharmacokinetic profiles of small mole-
cule drug candidates and biologicals,
including antibodies targeting host and
pathogen components (Katoh and Yokoi,
2007). The observed drug metabolism
profiles indicate that HuHEP mice will be
useful for predicting human drug interac-
tions, as well as endogenous enzyme
induction and inhibition, all of which are
serious concerns in drug development.
Despite proven utility in a variety of
applications, and the fact that this tech-
nology was first described almost a
decade ago, human liver chimeric mice
have not found wide-spread distribution.
Major obstacles to the availability andCell Host & Miapplication of HuHEP mouse technology
include very low throughput of chimeric
mice generation and substantial variation
in levels of human chimerism achieved
(Mercer et al., 2001; Meuleman et al.,
2005). Both issues can be attributed
to the substantial technical challenges
of humanizing the mouse liver, which
requires advanced surgical techniques
as well as intricate logistics to match
availability of scarce primary human
hepatocytes and suitable murine recipi-
ents. Increasing the time window for
transplant by generating models in which
liver injury is controllable, for example by
using inducible versions of the albumin
or major urinary protein (MUP) promoters
that drive uPA transgene expression later
in postnatal development, could increase
flexibility in the generation of HuHEP
mice. Another promising alternative is to
create mice with targeted disruptions in
fumarylacetoacetate hydrolase (FAH),crobe 6, July 23, 2009 ª2009 Elsevier Inc. 7
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nemia and liver failure in humans (Azuma
et al., 2007). FAH knockout mice can
be rescued by treatment of pregnant
mothers with 2(2-nitro-4-trifluoromethyl-
benzoyl)-1,3 cyclohexane dione (NTBC)
and liver injury can be induced at will by
withdrawal of the drug. It remains to be
seen, however, if any of these methods
can reproducibly achieve the high hepatic
reconstitution levels essential for human
infectious disease modeling and down-
stream applications such as pharmaceu-




Mice with humanized immune systems
already represent the model of choice
for various lymphotropic pathogens,
including HIV, EBV, and Kaposi’s
sarcoma-associated herpes virus (KSHV).
The addition of human hepatic tissue
holds promise for the study of hepato-
tropic pathogens, such as HBV, HCV,
dengue virus, yellow fever virus, and
malaria (Shultz et al., 2007), all of which
previously lacked accurate and amenable
in vivo models (Figure 1). Other areas
of investigation, such as autoimmune
processes and human tumorigenesis, are
also benefiting from humanized mouse
technology (Shultz et al., 2007). Mouse
models that combine several humanized
compartments will increase the specific
questions that can be addressed, and
a collection of humanized mice ‘‘on
demand’’ could be envisaged. For
example, mice with a human immune
system and supplementary human lung
tissue could model tuberculosis or
cytomegalovirus (CMV) pathogenesis.
Furthermore, preclinical evaluation of
vaccine potency could be performed in
mice engrafted with tissues efficiently
supporting various pathologies, and
safety, efficacy, and pharmacokinetics
studies of drugs and therapeutic biologi-
cals could be addressed in a tissue- and
cell subset-specific manner.
Combining immune and tissue subsets
is only a starting point to further address
the pathology, immune correlates, and
mechanisms of persistence of highly
specialized pathogens. HCV is one such
uniquely human liver-tropic virus with
limited treatment and prevention options.
A humanized mouse model that can reli-8 Cell Host & Microbe 6, July 23, 2009 ª200ably ‘‘read-out’’ HCV-specific immune
responses will find broad application in
understanding the interaction between
HCV and host, a process currently poorly
understood at both the cellular and
systemic levels. Understanding how HCV
is detected by the immune system, why
the majority of individuals fail to mount
an effective response, the factors involved
in chronic viral persistence versus resolu-
tion of infection, and whether immune
responses can be stimulated to eliminate
the virus will foster the development
of preventive and possibly therapeutic
vaccines. A suitable small animal model
would be an invaluable complement to
guide more challenging and expensive
studies in humans and experimentally
infected chimpanzees.
The construction of mice combining
human immune and liver cells will require
a highly specialized tissue procurement
system. Technical concerns include the
best sources of human tissue, timing of
transplantation, identification of optimal
murine hosts, and the extent of pre-
engraftment conditioning regimens. To
avoid the potential complication of tissue
histo-incompatibilities, isolation of hema-
topoietic and hepatic progenitors should
ideally be performed from the same donor
material. While this can be achieved using
human fetal liver tissue, availability of
this material is limited due to legislative,
ethical, and cultural issues. Alternative
sources of progenitor cells exist, including
hepatocytes isolated from adult liver,
hematopoietic stem cells (HSC) harvested
from umbilical cord blood, adult bone
marrow, or adult mobilized peripheral
blood, and material derived from differen-
tiated embryonic stem cells and induced
pluripotent stem (iPS) cell lines. Once
protocols for directed differentiation of
stem cells into hepatocytes andHSC yield
reliable results, such cells would be an
ideal source of transplantable material,
since they can be generated in potentially
unlimited quantities, further increasing the
throughput, robustness, and reproduc-
ibility of these models (Figure 1).
Making Humanized Mouse
Technology Broadly Accessible
In order to effectively integrate humanized
mouse technology into the drug and
vaccine development process, the tech-
nology must be widely accessible and
highly reproducible and allow the produc-9 Elsevier Inc.tion of large numbers of animals at
a reasonable cost. Humanizing mice
is demanding and not only requires
advanced technical skills but also an intri-
cate logistical setup. A practical and
possibly cost-effective short-term solu-
tion could be large-scale generation of
humanized mice by third party providers
who are also equipped to execute
custom-designed drug treatment and
vaccination regimens against human
pathogens, thereby reducing costly setup
and maintenance of biocontainment
facilities.
The scarcity of human primary material
mandates better coordination of cord
blood and fetal tissue procurement for
nonclinical research and development.
Hematopoietic stem cell and hepatocyte
isolation and storage must be harmo-
nized. A central distribution of quality-
controlled, HLA-typed material, similar
to clinical cord blood banks, would
allow the most effective use of these
limited resources. Additional innovative
approaches will be required to create
renewable ‘‘off-the-shelf’’ cell sources.
Protocols for stepwise and directed differ-
entiation of embryonic stem cells, and
more recently iPS cells, into hepatocytes
and HSCs, are currently being optimized.
Future challenges lie in validating the
in vivo engraftment potential and increas-
ing the production throughput of these
cells.
Concluding Remarks
The complex challenge of modeling
the most devastating and intractable of
human diseases can only be achieved
through a concerted, multidisciplinary
andmulti-institutional effort. The scientific
and technological competence required
for such efforts covers a wide spectrum
of expertise (technical, logistical, ethical),
making international collaboration in this
endeavor highly attractive. Under the
constructive leadership of the Bill &
Melinda Gates Foundation, efforts are
shared between partners within each
humanized mouse consortium, as well as
between consortia. By gathering multiple
fields of expertise from academic and
industrial partners, the consortium struc-
ture ensures a true collaboration between
highly motivated teams. Although this
fresh approachatworldwidecollaboration
will doubtlessly promote novel models
for infectious disease, it would be
Cell Host & Microbe
Forumshortsighted to rely exclusively on the
support of philanthropic organizations.
Given the significance of these medical
problems and the potential impact of this
technology, it is critical for policy makers
and their federal funding agencies to
invest in this area. Industries would also
benefit from participating in existing
multidisciplinary partnerships, since their
engagement will ensure that the demands
of pharmaceutical discovery pipelines are
adequately addressed during the technol-
ogy’s development and provide them
early access to it. These new tools, which
are critical for thedevelopment of effective
and affordable vaccines and therapeutics,
will begin to tackle the urgent health prob-
lems confronting our global community.
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